Ramakumar Tummala
Overview
Explore the profile of Ramakumar Tummala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tummala R, Lou W, Gao A, Nadiminty N
Mol Cancer Ther
. 2017 Jul;
16(12):2770-2779.
PMID: 28729398
Prostate cancer remains dependent on androgen receptor signaling even after castration. Aberrant androgen receptor signaling in castration-resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor...
12.
Tummala R, Nadiminty N, Lou W, Evans C, Gao A
Prostate
. 2015 Dec;
76(5):445-55.
PMID: 26714839
Background: Prostate cancer (PCa) is androgen-dependent initially and progresses to a castration-resistant state after androgen deprivation therapy. Treatment options for castration-resistant PCa include the potent second-generation anti-androgen enzalutamide or CYP17A1...
13.
Nadiminty N, Tummala R, Liu C, Lou W, Evans C, Gao A
Mol Cancer Ther
. 2015 Jun;
14(8):1884-95.
PMID: 26056150
Castration-resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signaling. Alternative splicing of the AR to generate constitutively active, ligand-independent variants is one of the principal mechanisms that promote...
14.
Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao A
Prostate
. 2013 Aug;
73(15):1614-22.
PMID: 23922223
Introduction: Treatment of primary prostate cancer (CaP) is the withdrawal of androgens. However, CaP eventually progresses to grow in a castration-resistant state due to aberrant activation of androgen receptor (AR)....
15.
Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans C, et al.
Mol Cancer Ther
. 2013 Jul;
12(9):1829-36.
PMID: 23861346
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, relapse eventually occurs due to the development of resistance to docetaxel. To unravel the mechanism of acquired docetaxel resistance,...
16.
Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen H, et al.
Am J Pathol
. 2013 Jun;
183(1):288-95.
PMID: 23790802
Prostate cancer (CaP) progresses to a castration-resistant state assisted by multifold molecular changes, most of which involve activation of the androgen receptor (AR). Having previously demonstrated the importance of the...
17.
Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans C, et al.
Mol Cancer Ther
. 2013 May;
12(8):1629-37.
PMID: 23699654
Resistance of prostate cancer cells to the next-generation antiandrogen enzalutamide may be mediated by a multitude of survival signaling pathways. In this study, we tested whether increased expression of NF-κB2/p52...
18.
Nadiminty N, Tummala R, Lou W, Zhu Y, Shi X, Zou J, et al.
PLoS One
. 2012 Apr;
7(3):e32832.
PMID: 22479342
Purpose: Prostate cancer (PCa) is characterized by deregulated expression of several tumor suppressor or oncogenic miRNAs. The objective of this study was the identification and characterization of miR-let-7c as a...
19.
Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, et al.
J Biol Chem
. 2011 Dec;
287(2):1527-37.
PMID: 22128178
Castration-resistant prostate cancer continues to rely on androgen receptor (AR) expression. AR plays a central role in the development of prostate cancer and progression to castration resistance during and after...
20.
Liu C, Nadiminty N, Tummala R, Chun J, Lou W, Zhu Y, et al.
Genes Cancer
. 2011 Jul;
2(2):151-9.
PMID: 21779488
Androgen receptor (AR) signaling not only plays a pivotal role in the development of androgen-dependent prostate cancer but is also important in the growth and survival of castration-resistant prostate cancer...